U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07335081) titled 'ctDNA in HER2+ EBC Neoadjuvant Treatment' on Dec. 21, 2025.
Brief Summary: This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T>=2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy
Study Start Date: Feb. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: pyrotinib
pyrotinib 320mg p.o. qd
DRUG: pertuzu...